Table 1.
Characteristics of 98 study subjects
| Mean (SD) | |
|---|---|
| Age (years) | 71.2 (6.9) |
| Duration of BP use (months) | 59.9 (34.3) |
| Serum concentration of corrected calcium (mg/dl) | 9.20 (0.40) |
| Serum BAP (μg/L) | 10.9 (3.7) |
| Urinary NTx (nmol BCE/mmol Cr) | 24.9 (10.2) |
| BMD of the lumbar spine 2 years before baseline (g/cm2) | 0.863 (0.097) |
| BMD of the lumbar spine at baseline (g/cm2) | 0.854 (0.100) |
| Change of BMD from 2 years before baseline at the lumbar spine (g/cm2) | −0.009 (0.027) |
| BMD of the lumbar spine at 1 year of denosumab treatment (g/cm2) | 0.893 (0.105) |
| Change of BMD from baseline to 1 year later at the lumbar spine for denosumab treatment (g/cm2) | 0.040 (0.031) |
| BMD of the hip 2 years before baseline (g/cm2) | 0.726 (0.079) |
| BMD of the hip at baseline (g/cm2) | 0.719 (0.081) |
| Change of BMD from 2 years before baseline at the hip at (g/cm2) | −0.007 (0.020) |
| BMD of the hip 1 year of denosumab treatment (g/cm2) | 0.733 (0.082) |
| Change of BMD from baseline to 1 year later at hip for denosumab treatment (g/cm2) | 0.015 (0.015) |
BMD bone mineral density, BAP bone specific alkaline phosphatase, NTx N-terminal telopeptide of type I collagen corrected by creatinine, BP bisphosphonate